Product Description
Palifermin is a recombinant human form of KGF. Because of its ability to cause proliferation of the oral mucosa and to protect against mucosal injury, palifermin is a treatment option for patients who are at high risk for oral mucositis, specifically patients with hematological malignancies receiving stem cell transplantation (SCT). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16390600/)
Mechanisms of Action: FGFR Agonist
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | European Medicines Agency | Germany | Hungary | Ireland | Italy | Lithuania | Portugal | Slovenia | Sweden | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Sobi
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Burns Unspecified|Burns, Chemical|Eye Burns|Keratoconjunctivitis Sicca
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20210423 | P1 |
Not yet recruiting |
Keratoconjunctivitis Sicca|Eye Burns|Burns, Chemical|Burns Unspecified |
None |